A phase 1 clinical trial evaluating an investigational vaccine for protection against coronavirus disease 2019 (COVID-19) has been initiated at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.
Nasopharyngeal pneumococcal and acute otitis media isolates from children have exhibited reduced susceptibility to several antibiotic classes after the introduction of PCV-13.
A rotavirus vaccination program led to significant and sustained reductions in both hospitalizations and emergency department visits across the US.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
D46/NS2/N/ΔM2-2-HindIII vaccine candidate had excellent infectivity and immunogenicity, and is primed for anamnestic responses.
The FDA has approved Fluad Quadrivalent for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.
Primary vaccination against hepatitis B virus (HBV) at birth may not provide adequate lifelong antibody levels, but a booster vaccine at age 18 years reinforces antibody levels for at least 4 more years.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
Triplex, a modified recombinant attenuated poxvirus vaccine engineered to induce a virus-specific T-cell response to control CMV in recipients of allogeneic hematopoietic stem cell transplant was safe and well tolerated.
The CDC continues to recommend influenza vaccination as the best method of protection while the viruses are circulating in the community.
